The predictive capacity of in vitro preclinical models to evaluate drugs for the treatment of retinoblastoma.

Irina L Sinenko, Roland C Turnell-Ritson, Francis L Munier, Paul J Dyson

Journal: Experimental eye research 2023;230():109447

PMID: 36940901

Free Full Text on Elsevier Science View on PubMed

Abstract

Retinoblastoma is a rare childhood cancer of the eye. Of the small number of drugs are used to treat retinoblastoma, all have been repurposed from drugs developed for other conditions. In order to find drugs or drug combinations better suited to the improved treatment of retinoblastoma, reliable predictive models are required, which facilitate the challenging transition from in vitro studies to clinical trials. In this review, the research performed to date on the development of 2D and 3D in vitro models for retinoblastoma is presented. Most of this research was undertaken with a view to better biological understanding of retinoblastoma, and we discuss the potential for these models to be applied to drug screening. Future research directions for streamlined drug discovery are considered and evaluated, and many promising avenues identified.

Address: Institute of Chemical Sciences and Engineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015, Lausanne, Switzerland; Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, CH-1004, Lausanne, Switzerland.; Institute of Chemical Sciences and Engineering, École Polytechnique Fédérale de Lausanne (EPFL), CH-1015, Lausanne, Switzerland.; Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, CH-1004, Lausanne, Switzerland. Electronic address: [email protected].

DOI: 10.1016/j.exer.2023.109447

Link outs

Free resources

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0014...

Subscription / membership required

Full Text Sources:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linko...

MeSH Terms: Humans, Child, Retinoblastoma, Drug Evaluation, Preclinical, Retinal Neoplasms